HHS awards $3.5M contract for novel microneedle drug delivery device development

Contract Overview

Contract Amount: $3,500,000 ($3.5M)

Contractor: Satio Inc

Awarding Agency: Department of Health and Human Services

Start Date: 2023-09-30

End Date: 2026-02-03

Contract Duration: 857 days

Daily Burn Rate: $4.1K/day

Competition Type: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Number of Offers Received: 3

Pricing Type: FIRM FIXED PRICE

Sector: R&D

Official Description: DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG

Place of Performance

Location: BOSTON, SUFFOLK County, MASSACHUSETTS, 02210

State: Massachusetts Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $3.5 million to SATIO INC for work described as: DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG Key points: 1. Focus on developing a low-cost, remotely controllable, disposable microneedle transdermal drug delivery system. 2. Contract aims to enable delivery of FDA-approved transdermal drugs. 3. Research and Development in Physical, Engineering, and Life Sciences is the primary sector. 4. The contract is a Definitive Contract with a Firm Fixed Price structure. 5. Awarded by the National Institutes of Health (NIH) within HHS. 6. The contractor, SATIO INC, will perform work over approximately 857 days. 7. This contract is not a small business set-aside.

Value Assessment

Rating: good

The contract value of $3.5 million for the development of a novel drug delivery device appears reasonable given the R&D nature of the work. Benchmarking against similar early-stage technology development contracts is challenging due to the unique nature of the 'SATIORX' device. However, the firm fixed-price structure suggests that the government has a clear understanding of the scope and cost, which can be advantageous for value.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under 'Full and Open Competition after Exclusion of Sources.' While this indicates an initial intent for broad competition, the 'exclusion of sources' clause suggests that specific sources may have been considered or excluded based on certain criteria before the final award. The number of bidders is not explicitly stated, but the 'full and open' designation implies a competitive process was intended.

Taxpayer Impact: A full and open competition, even with exclusions, generally aims to achieve the best value for taxpayers by soliciting offers from a wide range of potential contractors, which can drive down prices and encourage innovation.

Public Impact

Patients who could benefit from more efficient and user-friendly transdermal drug delivery methods. Development of a new platform technology for drug administration. Potential for broader application across various FDA-approved transdermal drugs. Advancement of biomedical engineering and nanotechnology research within the US. Support for innovation in the pharmaceutical and medical device industries.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

The 'exclusion of sources' clause warrants further investigation to understand the rationale and potential impact on competition.
The novelty of the technology may present inherent technical risks during development.
Reliance on a single contractor for this specific development phase could pose a risk if unforeseen issues arise.

Positive Signals

The firm fixed-price contract provides cost certainty for the government.
The development of a low-cost, disposable device aligns with potential for widespread adoption and affordability.
The focus on a remotely controllable system suggests potential for improved patient compliance and monitoring.
NIH funding indicates alignment with national health research priorities.

Sector Analysis

This contract falls within the Research and Development (R&D) sector, specifically focusing on physical, engineering, and life sciences. The market for drug delivery devices is substantial and growing, driven by advancements in pharmaceuticals and a demand for more effective and patient-friendly administration methods. This contract represents investment in a specific niche of that market: microneedle transdermal delivery, a technology with significant potential to improve drug efficacy and patient experience.

Small Business Impact

This contract was not awarded as a small business set-aside. There is no explicit information provided regarding subcontracting plans for small businesses. The focus on a specialized R&D project may not lend itself to extensive subcontracting opportunities for small businesses unless they possess highly specific niche expertise required by the prime contractor.

Oversight & Accountability

The National Institutes of Health (NIH) is responsible for overseeing this contract. As part of the Department of Health and Human Services (HHS), NIH is subject to various federal oversight mechanisms, including potential reviews by the HHS Office of Inspector General (OIG). The firm fixed-price nature of the contract provides a degree of financial accountability, and the definitive contract structure allows for clear milestones and deliverables to be monitored.

Related Government Programs

NIH Research and Development Contracts
Transdermal Drug Delivery Systems
Biomedical Device Development
Microneedle Technology Research

Risk Flags

Novel technology development carries inherent technical risks.
Reliance on a single contractor for a specific development phase.
Justification for 'exclusion of sources' requires scrutiny.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $3.5 million to SATIO INC. DEVELOPMENT OF DIGITAL SATIORX, A VERY LOW COST REMOTELY CONTROLLABLE DISPOSABLE MICRONEEDLE TRANSDERMAL DRUG DELIVERY DEVICE ABLE TO DELIVER ANY LIQUID FDA APPROVED TRANSDERMAL DRUG

Who is the contractor on this award?

The obligated recipient is SATIO INC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $3.5 million.

What is the period of performance?

Start: 2023-09-30. End: 2026-02-03.

What is the specific innovation behind the 'SATIORX' device and its potential advantages over existing transdermal delivery methods?

The 'SATIORX' device is described as a 'very low cost remotely controllable disposable microneedle transdermal drug delivery device.' Its key innovation lies in the combination of these features. Microneedles offer a way to bypass the stratum corneum, the outermost layer of skin, to enhance drug absorption, potentially improving efficacy and allowing for the delivery of molecules that are poorly absorbed orally. The 'remotely controllable' aspect suggests a sophisticated mechanism for drug release, possibly allowing for timed or on-demand administration, which could improve patient compliance and therapeutic outcomes. The 'disposable' and 'very low cost' attributes aim to make the technology accessible and practical for widespread use, differentiating it from potentially more complex or expensive existing transdermal systems or alternative delivery methods.

How does the $3.5 million contract value compare to similar R&D efforts in advanced drug delivery systems?

Benchmarking the $3.5 million contract value for the development of the 'SATIORX' device against similar R&D efforts is complex due to the unique combination of features (low cost, remote control, microneedles) and the early stage of development. However, R&D contracts for novel medical devices, especially those involving advanced materials, microfabrication, and wireless control, can range significantly. Early-stage feasibility and prototype development contracts can be in the low millions, while later-stage clinical trials and manufacturing scale-up can cost tens or hundreds of millions. Given that this contract focuses on the 'development' phase of a specific device, $3.5 million appears to be a reasonable allocation for exploring the technical feasibility and initial design of such an innovative system, assuming a well-defined scope of work.

What are the primary technical risks associated with developing a remotely controllable, disposable microneedle drug delivery device?

Developing a remotely controllable, disposable microneedle drug delivery device presents several technical risks. Firstly, the microneedle array itself must be reliably manufactured at low cost while ensuring consistent performance and safety (e.g., avoiding skin irritation or breakage). Secondly, the 'remotely controllable' aspect requires integrating a reliable and miniaturized control mechanism, which could involve microfluidics, actuators, or wireless communication components, all of which need to function accurately and be compatible with drug formulations. Thirdly, ensuring the sterility and stability of the drug within the disposable device until administration is critical. Finally, the device must be user-friendly and integrate seamlessly with various FDA-approved transdermal drugs, requiring extensive compatibility testing and potential formulation adjustments.

What is the expected timeline for the development and potential market entry of the SATIORX device based on this contract?

This contract has a duration of approximately 857 days, ending on February 3, 2026. This timeframe suggests the contract covers the core development phase, likely including design, prototyping, initial testing (bench and possibly preclinical), and refinement of the technology. It is unlikely that this contract alone covers full clinical trials, regulatory approval (e.g., FDA submission and review), and commercial manufacturing scale-up. Therefore, while significant progress is expected by February 2026, the actual market entry of the SATIORX device would likely occur several years after the completion of this development contract, contingent on successful subsequent phases of testing, validation, and regulatory clearance.

How does the 'Full and Open Competition after Exclusion of Sources' procurement method impact the potential for innovation and cost-effectiveness?

The 'Full and Open Competition after Exclusion of Sources' method is a nuanced approach. 'Full and Open Competition' is generally the preferred method as it maximizes the pool of potential offerors, fostering innovation and driving competitive pricing. However, the 'after Exclusion of Sources' qualifier indicates that certain potential sources were deliberately excluded prior to the solicitation. The impact on innovation and cost-effectiveness depends heavily on the justification for these exclusions. If sources were excluded based on a lack of specific, critical capabilities or past performance necessary for this highly specialized R&D, then the remaining competition might still yield innovative solutions and fair prices. Conversely, if exclusions were arbitrary or overly restrictive, it could limit the competitive landscape, potentially stifling innovation and leading to less favorable pricing for the government.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: 75N91023R00041

Offers Received: 3

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 27 DRYDOCK AVE, BOSTON, MA, 02210

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $3,500,000

Exercised Options: $3,500,000

Current Obligation: $3,500,000

Actual Outlays: $3,500,000

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline